BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31320153)

  • 21. Prevalence of Inadequate Cervical Cancer Screening in Low-Income Older Women.
    Cejtin HE; Schmidt JB
    J Womens Health (Larchmt); 2020 Oct; 29(10):1350-1353. PubMed ID: 32155360
    [No Abstract]   [Full Text] [Related]  

  • 22. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study.
    Maura G; Chaignot C; Weill A; Alla F; Heard I
    Eur J Cancer Prev; 2018 Sep; 27(5):479-485. PubMed ID: 28368950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
    Petry KU; Barth C; Wasem J; Neumann A
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
    Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
    Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and risk factors for human papillomavirus DNA in cervical cytology.
    Kasap B; Yetimalar H; Keklik A; Yildiz A; Cukurova K; Soylu F
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):168-71. PubMed ID: 21764503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Squamous cell carcinoma of the cervix: a cytology-histology-human papillomavirus correlation in clinical practice.
    Miller RA; Waters LL; Mody DR; Tams KC
    Arch Pathol Lab Med; 2015 Jun; 139(6):776-81. PubMed ID: 26030246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Melnikow J; Henderson JT; Burda BU; Senger CA; Durbin S; Weyrich MS
    JAMA; 2018 Aug; 320(7):687-705. PubMed ID: 30140883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden and genotype distribution of high-risk Human Papillomavirus infection and cervical cytology abnormalities at selected obstetrics and gynecology clinics of Addis Ababa, Ethiopia.
    Ali KE; Mohammed IA; Difabachew MN; Demeke DS; Haile T; Ten Hove RJ; Kumssa TH; Woldu ZL; Haile EL; Tullu KD
    BMC Cancer; 2019 Aug; 19(1):768. PubMed ID: 31382907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
    Qin J; Shahangian S; Saraiya M; Holt H; Gagnon M; Sawaya GF
    Gynecol Oncol; 2021 Nov; 163(2):378-384. PubMed ID: 34507826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation.
    Othman N; Othman NH
    Asian Pac J Cancer Prev; 2014; 15(5):2245-9. PubMed ID: 24716964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
    Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
    Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
    Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
    Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2018 Aug; 320(7):674-686. PubMed ID: 30140884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coverage rate of cervical cytology and HPV DNA test for cervix cancer screening: Reappraisal on impact of COVID-19 outbreak.
    Sookaromdee P; Wiwanitkit V
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S1020-S1021. PubMed ID: 38384106
    [No Abstract]   [Full Text] [Related]  

  • 37. [New strategies for the prevention and control of cervical cancer in Chile.].
    Ferreccio C
    Salud Publica Mex; 2018; 60(6):713-721. PubMed ID: 30699276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
    Kulkarni A; Chen L; Gockley A; Khoury-Collado F; Hou J; Clair CST; Melamed A; Hershman DL; Wright JD
    Gynecol Oncol; 2023 Aug; 175():53-59. PubMed ID: 37327539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variation in cervical cancer screening test utilization and results in a United States-based program.
    Dorismond VG; Saraiya M; Gopalani SV; Soman A; Kenney K; Miller J; Sawaya GF
    Gynecol Oncol; 2024 May; 184():96-102. PubMed ID: 38301312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical cervical cytomorphologic predictors: a descriptive study of pre-cervical cancer patients of low education in Kenya.
    Muitta E; Were T; Nyamache AK; Muhoho N
    Pan Afr Med J; 2019; 33():124. PubMed ID: 31558923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.